MSH|^~\&|LAB|LMH|||202002181010||ORU^R01|4169797|D|2.3|||AL|NE
PID|1||LM00005528|LM5330|LUMEDTEST^TORONTO^||19880908|F||||||||||LM000762/19|9874745485
OBR|1|39469^LAB|00029778^1802:C00003R^LAB^180220:C3^39469|500.2500^CRE^Creatinine \T\ EGFR^^^45066-8||202002180905|202002180905|||||||202002180905||||||||||LAB|F||||
OBX|1|ST|500.2600^CR^Creatinine Modified Jaffe^^14682-9^14682-9|1|200^^Y|umol/L|45-90|H||A^S|C|||202002181010
NTE|1||   ****   CORRECTED RESULT  ****
NTE|2||   ---  18/02/20 1010 ---
NTE|3||  CR previously reported as: 100 # H umol/L
NTE|4||
NTE|5||
OBX|2|ST|500.2700^EGFR^Glomerular Filtration Rate Est^^33914-3^33914-3|1|28^^Y|mL/min|>60|L||A^S|C|||202002181010
NTE|1||   ****   CORRECTED RESULT  ****
NTE|2||   ---  18/02/20 1010 ---
NTE|3||  EGFR previously reported as: 65 mL/min
NTE|4||
NTE|5||
OBR|2|39469^LAB|00029778^1802:C00003R^LAB^180220:C3^39469|500.5800^CK^Creatine Kinase^^2157-6^2157-6||202002180905|202002180905|||||||202002180905||||||||||LAB|F||||
OBX|1|ST|500.5800^CK^Creatine Kinase^^2157-6^2157-6|1|< 5^^Y|U/L|<140|N||A^S|F|||202002181010
OBR|3|39469^LAB|00029778^1802:C00003R^LAB^180220:C3^39469|500.6900^CRPH^C-Reactive Protein High Sens^^30522-7^30522-7||202002180905|202002180905|||||||202002180905||||||||||LAB|F||||
OBX|1|ST|500.6900^CRPH^C-Reactive Protein High Sens^^30522-7^30522-7|1|50.0^^Y|mg/L|<7.5|H||A^S|F|||202002181010
NTE|1||This high sensitivity CRP method is sensitive to 0.3 mg/L
NTE|2||and is suitable for coronary artery risk assessment:
NTE|3||                         Less than 1.0 mg/L  low risk;
NTE|4||                         1.0 - 3.0 mg/L  intermediate risk;
NTE|5||                         Greater than 3.0 mg/L  high risk.
NTE|6||Values greater than 7.5 mg/L are significant for active
NTE|7||inflammation or infection and require follow up as
NTE|8||clinically needed. For consultation on specific patient
NTE|9||cases call your site Medical Biochemist. Interpretation
NTE|10||should be based on full history and other risk assessment
NTE|11||factors.